Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden (Analysis of Data from the MOST Study)

Roger Lyons, David Lessen, Salman Fazal, Robyn Scherber, Patricia Kalafut, Haobo Ren, Ellen Ritchie

Blood (2021) 138 (Supplement 1): 1497.

https://doi.org/10.1182/blood-2021-145909

Published: 2021

Journal Articles

Real-World Patterns of Molecular Genetic Testing Among Patients with Acute Myeloid Leukemia in US Community Oncology Settings

Roger Lyons, Sneha Sura, Srinivas Annavarapu, Jackie Kwong, Albert Fliss

Blood (2021) 138 (Supplement 1): 4980.

https://doi.org/10.1182/blood-2021-147008

Published: 2021

Journal Articles

Extended Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy in the Community-Based United States (US) MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation

Robert M. Rifkin, Stephen J. Noga, Saulius K. Girnius, Kimberly Bogard, Sudhir Manda, Habte Yimer, Presley Whidden, Ruemu E. Birhiray, Philip Twumasi-Ankrah, Yikun Guo, Rami Owera, Leon Bernal-Mizrachi, Roger Lyons

Blood (2021) 138 (Supplement 1): 2726.

https://doi.org/10.1182/blood-2021-150094

Published: 2021

Journal Articles

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Blood (2021) 138 (Supplement 1): 4669.

https://doi.org/10.1182/blood-2021-145626

Published: 2021

Journal Articles

Once-Weekly Carfilzomib with Dexamethasone Demonstrated Promising Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma Regardless of Age and Prior Bortezomib Exposure

Jesus G. Berdeja, MD, Robert M. Rifkin, MD, Roger Lyons, MD, Hui Yang, Anita Zahlten-Kuemeli, Sanjay K. Aggarwal, Karim Iskander, PhD, James Berenson, MD

Blood (2016) 128 (22): 2129.

https://doi.org/10.1182/blood.V128.22.2129.2129

Published: 2016

Journal Articles

Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)

James Berenson, MD, Alan Cartmell, Roger Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph V. Boccia, MD, Morton Coleman, Robert A. Moss, MD, Robert M. Rifkin, Marco Schupp, Sandra Dixon, Ying Ou, Janet Anderl, Jesus G. Berdeja, MD

Blood (2015) 126 (23): 373.

https://doi.org/10.1182/blood.V126.23.373.373

Published: 2015

Journal Articles

Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)

Jatin Shah, Ruben Niesvizky, MD, Edward Stadtmauer, Robert M. Rifkin, James Berenson, MD, Jesus G. Berdeja, MD, Jeff P. Sharman, MD, Roger Lyons, Zandra Klippel, MD, Hansen Wong, Yu-Lin Chang, Saad Usmani

Blood (2015) 126 (23): 378.

https://doi.org/10.1182/blood.V126.23.378.378

Published: 2015

Journal Articles

The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind, Double-Dummy, Symptom Study (RELIEF)

Ruben Mesa, MD, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD MB, Pierre Zachee, MD PhD, Mamta Garg, MD FRCP, FRCPath, Roger Lyons, MD, Silwan Chedid, MD, Steffen Koschmieder, MD, Ciro Rinaldi, MD PhD, Jennifer Byrne, MB, ChB, PhD FRCP, FRCPath, Yasmin Hasan, MD, Francesco Passamonti, MD, Srdan Verstovsek, MD PhD, Deborah Hunter, PhD, Mark M Jones, MD, Shui He, PhD, Alex Morozov, MD PhD, Bruno Martino, MD

Blood (2014) 124 (21): 3168.

https://doi.org/10.1182/blood.V124.21.3168.3168

Published: 2014

Journal Articles

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

Nicholas Di Bella, Raymond Taetle, Kathryn Kolibaba, Thomas Boyd, Robert Raju, David Barrera, Ernest W. Cochran, Jr, Philip Y. Dien, Roger Lyons, Peter J. Schlegel, Svetislava J. Vukelja, Julie Boston, Kristi A. Boehm, Yunfei Wang, Lina Asmar

Blood (2010) 115 (3): 475–480.

https://doi.org/10.1182/blood-2009-08-233155

Published: 2010

Journal Articles

An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).

Pierre Fenaux, Hagop Kantarjian, MD, Roger Lyons, Richard A. Larson, MD, Mikkael A. Sekeres, MD, MS, Pamela S. Becker, MD, PhD, Petra Muus, MD, PhD, Kuolong Hu, PhD, Dietmar Berger, MD, PhD, Janet L. Franklin, MD, MPH

Blood (2009) 114 (22): 2765.

https://doi.org/10.1182/blood.V114.22.2765.2765

Published: 2009

Journal Articles

Evaluation of AMG 531 Safety in Splenectomized (S) and Nonsplenectomized (NS) Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in Two Randomized Placebo-Controlled Phase 3 Studies

Roger Lyons, James N. George, Francois Lefrere, Alan E. Lichtin, Michael D. Tarantino, Howard R. Terebelo, Jean-Francois Viallard, Reggie Kelly, Matthew Guo, Janet Nichol

Blood (2007) 110 (11): 1300.

https://doi.org/10.1182/blood.V110.11.1300.1300

Published: 2007

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients (Pts) with Chronic Immune Thrombocytopenic Purpura (ITP): Results from Two Placebo-Controlled Phase 3 Studies of AMG 531.

James N. George, Roger Lyons, Francis J. Cuevas, Ronald S. Go, David H. Henry, Robert L. Redner, Lawrence Rice, Martin R. Schipperus, Susan D. Mathias, Sue Gao, Matthew Guo, Janet L. Nichol

Blood (2007) 110 (11): 1314.

https://doi.org/10.1182/blood.V110.11.1314.1314

Published: 2007

Journal Articles

Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment.

Hagop Kantarjian, Pierre Fenaux, Mikkael A. Sekeres, Pamela Becker, Adam Boruchov, David Bowen, Richard Larson, Roger Lyons, Petra Muus, Jamile Shammo, Michael Ehrman, Kuolung Hu, Janet Nichol

Blood (2007) 110 (11): 250.

https://doi.org/10.1182/blood.V110.11.250.250

Published: 2007

Journal Articles

The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndrome (MDS).

Hagop M. Kantarjian, MD, Francis Giles, MD, FRCPI, FRCPath, Alan F. List, MD, Roger Lyons, MD, Sherry Price, BSN, Robert Deuson, PhD, Joseph Leveque, MD

Blood (2006) 108 (11): 2617.

https://doi.org/10.1182/blood.V108.11.2617.2617

Published: 2006

Journal Articles

Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.

David Kuter, James Bussel, James George, Louis Aledort, Alan Lichtin, Roger Lyons, Jorge Nieva, Jeffrey Wasser, Emanuelle Bourgeois, Mies Kappers-Klunne, Francois Lefrere, Martin Schipperus, Reggie Kelly, Jenny Christal, Matthew Guo, Janet Nichol

Blood (2006) 108 (11): 476.

https://doi.org/10.1182/blood.V108.11.476.476

Published: 2006

Journal Articles

A Phase 2, Single-Arm, Open-Label Trial To Evaluate the Effectiveness of Darbepoetin alfa for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndrome.

Janice Gabrilove, Ron Paquette, Roger Lyons, Chaudhry Mushtaq, Mikkael Sekeres, Hung Lam, Lyndah Dreiling

Blood (2005) 106 (11): 2541.

https://doi.org/10.1182/blood.V106.11.2541.2541

Published: 2005

Journal Articles

Azacitidine (Vidaza®) Treatment Response Assessed Using Three Alternative Dosing Schedules in Patients with Myelodysplastic Syndromes (MDS).

Roger Lyons, MD, Thomas Cosgriff, MD, Sanjiv Modi, MD, Linda Lintz, BA, C.L. Beach, PharmD, Jay T. Backstrom, MD, MPH

Blood (2005) 106 (11): 2517.

https://doi.org/10.1182/blood.V106.11.2517.2517

Published: 2005

NARROW

Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden (Analysis of Data from the MOST Study)

Real-World Patterns of Molecular Genetic Testing Among Patients with Acute Myeloid Leukemia in US Community Oncology Settings

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Once-Weekly Carfilzomib with Dexamethasone Demonstrated Promising Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma Regardless of Age and Prior Bortezomib Exposure

Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)

Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)

The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind, Double-Dummy, Symptom Study (RELIEF)

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).

Evaluation of AMG 531 Safety in Splenectomized (S) and Nonsplenectomized (NS) Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in Two Randomized Placebo-Controlled Phase 3 Studies

Health-Related Quality of Life (HRQoL) in Patients (Pts) with Chronic Immune Thrombocytopenic Purpura (ITP): Results from Two Placebo-Controlled Phase 3 Studies of AMG 531.

Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment.

The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndrome (MDS).

Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.

A Phase 2, Single-Arm, Open-Label Trial To Evaluate the Effectiveness of Darbepoetin alfa for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndrome.

Azacitidine (Vidaza®) Treatment Response Assessed Using Three Alternative Dosing Schedules in Patients with Myelodysplastic Syndromes (MDS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only